Literature DB >> 15647761

Liver-specific expression of interferon gamma following adenoviral gene transfer controls hepatitis B virus replication in mice.

J Dumortier1, K Schönig, H Oberwinkler, R Löw, T Giese, H Bujard, P Schirmacher, U Protzer.   

Abstract

Interferons control viral replication and the growth of some malignant tumors. Since systemic application may cause severe adverse effects, tissue-specific expression is an attractive alternative. Liver-directed interferon gene therapy offers promising applications such as chronic viral hepatitis B or C or hepatocellular carcinoma and thus needs testing in vivo in suitable animal models. We therefore used the Tet-On system to regulate gene expression in adenoviral vectors, and studied the effect of liver-specific and regulated interferon gamma expression in a mouse model of chronic hepatitis B virus (HBV) infection. In a first generation adenoviral vector, genes encoding for firefly luciferase and interferons alpha, beta or gamma, respectively, were coexpressed under control of the bidirectional tetracycline-regulated promoter P(tet)bi. Liver-specific promoters driving expression of the reverse tetracycline controlled transactivator ensured local expression in the livers of HBV transgenic mice. Following gene transfer, we demonstrated low background, tight regulation and a 1000-fold induction of gene expression by doxycycline. Both genes within the bidirectional transcription unit were expressed simultaneously, and in a liver-specific fashion in cell culture and in living mice. Doxycycline-dependent interferon gamma expression effectively controlled HBV replication in mice, but did not eliminate HBV transcripts. This system will help to study the effects of local cytokine expression in mouse disease models in detail.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15647761     DOI: 10.1038/sj.gt.3302449

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  9 in total

1.  Liver-directed gamma interferon gene delivery in chronic hepatitis C.

Authors:  Eui-Cheol Shin; Ulrike Protzer; Andreas Untergasser; Stephen M Feinstone; Charles M Rice; Dana Hasselschwert; Barbara Rehermann
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

Review 2.  Cytokine-Mediated Immunopathogenesis of Hepatitis B Virus Infections.

Authors:  Xuefen Li; Xia Liu; Li Tian; Yu Chen
Journal:  Clin Rev Allergy Immunol       Date:  2016-02       Impact factor: 8.667

3.  APOBEC3-independent interferon-induced viral clearance in hepatitis B virus transgenic mice.

Authors:  Priscilla Turelli; Alexandra Liagre-Quazzola; Bastien Mangeat; Sonia Verp; Stephanie Jost; Didier Trono
Journal:  J Virol       Date:  2008-04-23       Impact factor: 5.103

4.  Induction of antiviral cytidine deaminases does not explain the inhibition of hepatitis B virus replication by interferons.

Authors:  Stéphanie Jost; Priscilla Turelli; Bastien Mangeat; Ulrike Protzer; Didier Trono
Journal:  J Virol       Date:  2007-07-25       Impact factor: 5.103

5.  Can engineered "designer" T cells outsmart chronic hepatitis B?

Authors:  U Protzer; H Abken
Journal:  Hepat Res Treat       Date:  2010-09-21

Review 6.  In vivo gene regulation using tetracycline-regulatable systems.

Authors:  Knut Stieger; Brahim Belbellaa; Caroline Le Guiner; Philippe Moullier; Fabienne Rolling
Journal:  Adv Drug Deliv Rev       Date:  2009-04-23       Impact factor: 15.470

7.  Switching on the lights for gene therapy.

Authors:  Alexandra Winkeler; Miguel Sena-Esteves; Leonie E M Paulis; Hongfeng Li; Yannic Waerzeggers; Benedikt Rückriem; Uwe Himmelreich; Markus Klein; Parisa Monfared; Maria A Rueger; Michael Heneka; Stefan Vollmar; Mathias Hoehn; Cornel Fraefel; Rudolf Graf; Klaus Wienhard; Wolf D Heiss; Andreas H Jacobs
Journal:  PLoS One       Date:  2007-06-13       Impact factor: 3.240

8.  In Situ Liver Expression of HBsAg/CD3-Bispecific Antibodies for HBV Immunotherapy.

Authors:  Robert L Kruse; Thomas Shum; Xavier Legras; Mercedes Barzi; Frank P Pankowicz; Stephen Gottschalk; Karl-Dimiter Bissig
Journal:  Mol Ther Methods Clin Dev       Date:  2017-08-31       Impact factor: 6.698

Review 9.  Gene Therapy for Chronic HBV-Can We Eliminate cccDNA?

Authors:  Kristie Bloom; Mohube Betty Maepa; Abdullah Ely; Patrick Arbuthnot
Journal:  Genes (Basel)       Date:  2018-04-12       Impact factor: 4.096

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.